Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report released on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

A number of other analysts also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $25.26 on Wednesday. Structure Therapeutics has a one year low of $24.95 and a one year high of $62.74. The firm has a market capitalization of $1.45 billion, a P/E ratio of -34.13 and a beta of -2.78. The company’s fifty day moving average is $32.03 and its two-hundred day moving average is $36.50.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors have recently made changes to their positions in GPCR. Wellington Management Group LLP increased its position in Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC boosted its stake in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after buying an additional 602,609 shares in the last quarter. Driehaus Capital Management LLC raised its position in shares of Structure Therapeutics by 3.5% in the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after buying an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Structure Therapeutics by 6.6% during the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.